A standalone M&A theme centered on acquiring Arsenal Medical and its developmental liquid embolic agent, NeoCast, to expand the technology portfolio for cerebrovascular treatment. The acquisition is also intended to accelerate expansion into endovascular treatment for chronic subdural hematoma.